Premium
Dose Proportionality of Oral Etoricoxib, a Highly Selective Cyclooxygenase‐2 Inhibitor, in Healthy Volunteers
Author(s) -
Agrawal Nancy G. B.,
Porras Arturo G.,
Matthews Catherine Z.,
Woolf Eric J.,
Miller Jutta L.,
Mukhopadhyay Saurabh,
Neu Donald C.,
Gottesdiener Keith M.
Publication year - 2001
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/00912700122012715
Subject(s) - etoricoxib , pharmacokinetics , medicine , crossover study , pharmacology , anesthesia , cyclooxygenase , chemistry , biochemistry , alternative medicine , pathology , enzyme , placebo
To assess dose proportionality of etoricoxib across the anticipated clinical dose range, a single panel of 12 healthy subjects was administered single oral doses of etoricoxib of 5,10, 20, 40, and 120 mg in an open, two‐part, five‐period crossover study. Plasma samples were collected after each dose and analyzed for etoricoxib concentrations. The pharmacokinetics of etoricoxib appear to be linear over the entire dose range examined, from 5 to 120 mg. Etoricoxib was found to be well tolerated across the 5 to 120 mg dose range.